Characteristic | Placebo (N = 17) | Fulranumab 9 mg (N = 14) |
---|---|---|
Sex, n (%) | Â | Â |
 Female | 13 (76.5) | 13 (92.2) |
 Male | 4 (23.5) | 1 (7.1) |
Race, n (%) | Â | Â |
 White | 16 (94.1) | 13 (92.9) |
 Black or African American | 1 (5.9) | 1 (7.1) |
Age (years) | Â | Â |
 Mean ± SD | 46.2 (13.56) | 50.6 (10.68) |
 Range | 25–69 | 38–78 |
Body weight (kg) | Â | Â |
 Mean ± SD | 78.9 (16.61) | 71.7 (26.12) |
 Range | 54–117 | 46–148 |
UPOINT clinical phenotyping, n (%) | Â | Â |
 Urinary | 17 (100) | 14 (100) |
 Psychosocial | 5 (29) | 3 (21) |
 Organ-specific | 16 (94) | 11 (79) |
 Infection | 4 (24) | 5 (36) |
 Neurological/systemic | 7 (41) | 9 (64) |
 Tender point | 12 (71) | 9 (64) |
Duration of interstitial cystitis (years) | Â | Â |
 Mean ± SD | 9.4 (9.87) | 5.8 (5.44) |
 Range | 2–40 | 1–20 |
Hunner’s ulcer and/or glomerulation, n (%) |  |  |
 Yes | 9 (52.9) | 10 (71.4) |
 No | 8 (47.1) | 4 (28.6) |